IL17A and lung carcinoma: Thus, therapeutic interventions addressing IL-17 cytokines and IL-17-signaling are a potential strategy to reduce pulmonary inflammation in chronic lung diseases, especially when combined with additional therapeutic approaches, such as immunotherapy in lung cancer.